{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-23-006796","form_type":"8-K","ticker":"ABUS","cik":"0001447028","company_name":"Arbutus Biopharma Corp","filed_at":"2023-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.101512+00:00","generated_at":"2026-06-08T14:35:05.627368+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Arbutus cuts workforce 24%, extends cash runway to Q1 2026; CEO to retire","bullets":["Workforce reduced by 24% affecting research; one-time charge ~$1.1M in Q4 2023.","Cash, cash equivalents & investments $144.7M as of Sep 30; cash runway extended into Q1 2026.","Net loss $20.1M ($0.12 per share) for Q3 2023 vs. $17.6M loss in Q3 2022.","CEO William Collier to retire at end of 2023; COO Michael McElhaugh to serve as interim CEO.","Preliminary Phase 2a data for imdusiran + VTP-300 at AASLD; AB-101 Phase 1a/1b dosing continues."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-23-006796","json":"https://secwatch.observer/filing/0001171843-23-006796.json","markdown":"https://secwatch.observer/filing/0001171843-23-006796.md","text":"https://secwatch.observer/filing/0001171843-23-006796.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1447028/000117184323006796/0001171843-23-006796-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1447028/000117184323006796/f8k_110623.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T14:35:05.627368+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0e7851efc15114796c88bdae154f99e823a83f85","claim":"Arbutus Biopharma Corp reported financial results for the third quarter ended September 30, 2023.","evidence_excerpt":"On November 7, 2023, Arbutus Biopharma Corporation (the “Company”) issued a press release announcing its financial results for the third quarter ended September 30, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1447028/000117184323006796/0001171843-23-006796-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}